Tempol protects human lymphocytes from genotoxicity induced by cisplatin.
2014; National Institutes of Health; Linguagem: Inglês
Autores
Omar F. Khabour, Karem H. Alzoubi, Doa'a S Mfady, Mohammed Alasseiri, Taghrid F Hasheesh,
Tópico(s)Carcinogens and Genotoxicity Assessment
ResumoThe use of cisplatin in treatments of human malignancies is limited by its side effects that include DNA damage and the subsequent risk of developing secondary cancer. In this study, we examined the possible protective effect of Tempol against DNA damage induced by cisplatin in human lymphocytes using chromosomal aberrations (CAs) and sister chromatid exchanges (SCEs) assays. Cisplatin induced significant elevation in the frequencies of CAs and SCEs in cultured human lymphocytes (P < 0.01). Treatment of lymphocytes with Tempol significantly lowered CAs and SCEs induced by cisplatin. Tempol alone did not affect spontaneous levels of SCEs and CAs observed in the control group (P > 0.05). In conclusion, Tempol protects human lymphocytes against genotoxicity induced by the anticancer drug cisplatin.
Referência(s)